4EGI-1 NEW
| Price | $37 | $50 | $90 |
| Package | 1mg | 2mg | 5mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-21 |
Product Details
| Product Name: 4EGI-1 | CAS No.: 315706-13-9 |
| Purity: 99.59% | Supply Ability: 10g |
| Release date: 2026/04/21 |
Product Introduction
Bioactivity
| Name | 4EGI-1 |
| Description | 4EGI-1, a competitive eIF4E/eIF4 g interaction inhibitor, binds to eIF4E(KD=25 μM). |
| Cell Research | Cell viability is measured by treatment of Jurkat cells with compound for 24 h and by determination of intracellular ATP using the CellTiterGlo assay. For measurement of apoptotic DNA fragmentation, cells are treated for 24 h with 60 μM EGI-1 or 6.65 μM camptothecin in the presence or absence of 100 mM zVAD-FMK, a broad-spectrum caspase inhibitor. After fixation and staining with PI, cellular DNA content is determined by FACS analysis in a FACS Calibur machine. Nuclear morphology after 24 h EG1-1 treatment is visualized by staining of cells with Hoechst dye and ?uorescence microscopy. For the A549 lung cancer cells, cell growth in the presence of 4EGI-1 is determined using the SRB staining method.(Only for Reference) |
| In vivo | In Jurkat cells, 4EGI-1 promotes apoptosis. It effectively inhibits cell growth in A549 lung cancer cells (IC50=6 μM). In human lung cancer cells, 4EGI-1 enhances TRAIL-induced apoptosis by inducing DR5 and downregulating c-FLIP, thereby inhibiting cap-dependent protein translation. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (221.59 mM), Sonication is recommended. |
| Keywords | Inhibitor | inhibit | Eukaryotic Initiation Factor (eIF) | eIF-4E/eIF-4G | Autophagy | Apoptosis | 4EGI-1 | 4EGI1 |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Urea | Guanidine hydrochloride | Hydroxychloroquine | Metronidazole | Formamide | Paeonol | Naringin | Daraxonrasib | Alginic acid |
| Related Compound Libraries | Bioactive Compound Library | Endoplasmic Reticulum Stress Compound Library | Kinase Inhibitor Library | Glutamine Metabolism Compound Library | Autophagy Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $119.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-04 | ||
|
VIP8Y
|
ROSEWA HOLDING GROUP CO.,LIMITED
|
2026-07-03 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY